Literature DB >> 7714781

Melatonin agonists modulate 5-HT2A receptor-mediated neurotransmission: behavioral and biochemical studies in the rat.

A S Eison1, R P Freeman, V B Guss, U L Mullins, R N Wright.   

Abstract

Interactions between melatonin and serotonin type 2A (5-HT2A) receptors in the regulation of the sleep-wakefulness cycle in the rat have been reported. We studied the acute effects of melatonin and related agonists on 5-HT2A neurotransmission as reflected in behavioral (head shake) and biochemical [phosphoinositide (PI) hydrolysis] responses to 5-HT2A receptor stimulation. Like 5-HT1A agonists and antidepressants, acute administration of melatonin and related agonists inhibited the 5-HT2A-mediated (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane-induced head shake in a dose-dependent manner. Consistent with these behavioral findings, in vitro incubation of cortical slices with melatonin agonists robustly inhibited 5-HT2A receptor-mediated PI hydrolysis in a noncompetitive manner. 2-Iodomelatonin-induced reductions in 5-HT2A-stimulated PI hydrolysis were blocked by preincubation with the melatonin antagonist N-acetyltryptamine. Further, pretreatment of rats in vivo with melatonin and related agonists reduced the cortical PI hydrolysis response to the 5-HT2A agonist alpha methyl-5-HT but did not alter cortical 5-HT2A receptor density. The present data support an interaction between melatonin and 5-HT2A receptors in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714781

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Regulation of rat cortical 5-hydroxytryptamine2A receptor-mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine.

Authors:  Gerard J Marek
Journal:  Eur Neuropsychopharmacol       Date:  2008-02-21       Impact factor: 4.600

2.  An endogenous 5-HT(7) receptor mediates pigment granule dispersion in Xenopus laevis melanophores.

Authors:  M T Teh; D Sugden
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

3.  Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models.

Authors:  Shao-wen Tian; Moshe Laudon; Li Han; Jun Gao; Fu-lian Huang; Yu-feng Yang; Hai-feng Deng
Journal:  Acta Pharmacol Sin       Date:  2010-06-28       Impact factor: 6.150

4.  Melatonin effects on serotonin synthesis and metabolism in the striatum, nucleus accumbens, and dorsal and median raphe nuclei of rats.

Authors:  J M Míguez; F J Martín; M Aldegunde
Journal:  Neurochem Res       Date:  1997-01       Impact factor: 3.996

5.  Melatonin.

Authors:  Paul Pévet
Journal:  Dialogues Clin Neurosci       Date:  2002-03       Impact factor: 5.986

6.  An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology.

Authors:  Leszek A Rybaczyk; Meredith J Bashaw; Dorothy R Pathak; Scott M Moody; Roger M Gilders; Donald L Holzschu
Journal:  BMC Womens Health       Date:  2005-12-20       Impact factor: 2.809

Review 7.  Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.

Authors:  Moshe Laudon; Anat Frydman-Marom
Journal:  Int J Mol Sci       Date:  2014-09-09       Impact factor: 5.923

8.  Therapeutic role of melatonin in migraine prophylaxis: A systematic review.

Authors:  Rujin Long; Yousheng Zhu; Shusheng Zhou
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.